Heart and vascular medicine
Trial results, device approvals and practice guidance across cardiology, interventional care and vascular medicine.
Cardiology
Cardiac procedural teams should reconcile every automated Impella controller against the FDA-listed removal, including units in use, storage, transport kits and biomedical engineering custody.
Rayan Salih · November 11, 2026 · 7 min
Cardiology
The first consolidated US multisociety guideline for adults with acute pulmonary embolism introduces an A-to-E severity taxonomy and gives Pulmonary Embolism Response Teams a class 1 recommendation.
Dr. Abu Bakar · 7 min read
Cardiology
In a randomized trial, TAVR lowered the two-year risk of death or heart-failure hospitalization in patients with moderate aortic stenosis and at-risk features.
Dr. Abu Bakar · 6 min read
Cardiology
SIMPLAAFY compared reduced-dose oral anticoagulation or aspirin alone with dual antiplatelet therapy after left atrial appendage closure, finding similar stroke rates and less bleeding over 6 months.
Dr. Abu Bakar · 6 min read
Cardiology
An FDA early alert concerns an Edwards transcatheter mitral-valve delivery system, but key scope and response details remain unavailable to structural-heart teams.
Rayan Salih · 6 min read
Cardiology
An FDA early alert flags an Edwards transcatheter mitral-valve delivery system, but the available record does not name a model, event count or corrective action.
Dr. Abu Bakar · 6 min read
Cardiology
The multicenter BASE trial will test cardiovascular and metabolic effects of beta-blocker therapy in people with aortic stenosis. Its protocol does not yet provide treatment-effect estimates.
Rayan Salih · 6 min read
Cardiology
In AMUNDSEN, evolocumab started before PCI rapidly lowered LDL cholesterol after acute myocardial infarction but did not improve clinical outcomes at 1 year.
Rayan Salih · 7 min read
Cardiology
The FDA's Class I correction covers catheter introducer kits used with Impella heart pumps. Bleeding complaints, including reports associated with deaths, make rapid product identification and clinical vigilance essential.
Rayan Salih · 7 min read
Cardiology
A randomized-trial review favors SGLT2 inhibitors for heart failure hospitalization, while mortality differences from GLP-1 receptor agonists remain less certain.
Dr. Abu Bakar · 6 min read
Cardiology
A meta-analysis of 10 randomized datasets and 37,923 participants found distinct cardiorenal outcome patterns across SGLT2 inhibitors, finerenone and semaglutide, arguing against treating them as interchangeable.
Rayan Salih · 7 min read
Cardiology
American Regent recalled one lot of papaverine hydrochloride injection because of glass and/or paraformaldehyde particles, prompting stock quarantine, administration tracing and postexposure review.
Rayan Salih · 6 min read
Cardiology
ITACS addresses IV iron before cardiac surgery, but the supplied citation lacks the numerical results needed to determine whether it reduces transfusion or improves recovery.
Rayan Salih · 6 min read
Cardiology
Across 35 randomized trials, high-dose omega-3 treatment was associated with higher atrial fibrillation risk. The absolute increase was modest but relevant for cardiovascular patients.
Rayan Salih · 6 min read
Cardiology
Across randomized heart-failure trials, SGLT2 inhibitors most reliably reduce worsening heart failure and cardiovascular death. Evidence for lower all-cause mortality is less secure.
Rayan Salih · 7 min read
Cardiology
A 2026 meta-analysis found that digitalis glycosides reduced worsening heart failure events, but not cardiovascular death, reinforcing a selective rather than routine role.
Dr. Abu Bakar · 7 min read
Cardiology
FDA approval adds baxdrostat as an aldosterone-targeted option for adults whose hypertension remains uncontrolled on combination therapy.
Rayan Salih · 7 min read
Cardiology
A 2026 meta-analysis estimated 32% lower odds of major cardiovascular events with semaglutide. The result supports cardiovascular benefit discussions but requires context on heterogeneity, absolute risk and indication.
Dr. Abu Bakar · 6 min read
Cardiology
In a randomized trial, acoramidis preserved patient-reported health status and reduced cardiovascular hospitalizations over 30 months in adults with transthyretin amyloid cardiomyopathy.
Rayan Salih · 7 min read
Cardiology
A randomized trial reported that stopping primary-prevention statins in adults 75 or older was noninferior to continuation for 3-year mortality. The confidence interval is central to applying that result.
Rayan Salih · 6 min read
Cardiology
FINEARTS-HF found that baseline blood pressure did not materially alter finerenone’s effect on cardiovascular death and total worsening heart failure events in patients with LVEF of 40% or higher.
Rayan Salih · 6 min read
Cardiology
A randomized-trial meta-analysis found less major bleeding with 3–6 months of DAPT after PCI than with 12 months, while major cardiovascular events were not significantly increased.
Rayan Salih · 6 min read
Cardiology
The 2026 CKM guideline calls for earlier, integrated prevention when cardiovascular, kidney and metabolic risks coexist, with action spanning primary care, endocrinology, nephrology and cardiology.
Dr. Abu Bakar · 7 min read
Cardiology
TRACK found no cardiovascular benefit and more major bleeding when low-dose rivaroxaban was added in stage 4–5 CKD or dialysis-dependent kidney failure.
Rayan Salih · 6 min read
Cardiology
The 2026 multisociety guideline defines a unified pathway for evaluating cardiovascular, kidney and metabolic risk, particularly when disease or risk factors overlap.
Rayan Salih · 7 min read
Cardiology
The DAPT-MVD citation alone does not provide enough verified numerical detail to weigh another year of clopidogrel plus aspirin after multivessel PCI.
Rayan Salih · 6 min read
Cardiology
The 2026 guideline retains a 130/80 mm Hg diagnostic threshold but links medication timing to cardiovascular, diabetes and kidney risk. Most treated adults share a target below 130/80 mm Hg.
Rayan Salih · 7 min read
Cardiology
The 2026 consensus sharpens how heart failure should be identified and documented when symptoms, cardiac abnormalities, biomarkers and evidence of congestion disagree.
Rayan Salih · 7 min read
Cardiology
FDA approval makes enlicitide the first oral PCSK9 inhibitor for adults who need additional LDL-C lowering despite maximally tolerated statins, including those with heterozygous familial hypercholesterolemia.
Rayan Salih · 6 min read
Cardiology
OPTIMA-AF supports stopping the P2Y12 inhibitor after 1 month in selected patients with atrial fibrillation undergoing PCI, reducing important bleeding without an apparent loss of thromboembolic protection.
Egbavwe Pela · 6 min read
Cardiology
Aortic regurgitation is a common heart valve problem where the aortic valve doesn’t close tightly.
Dr. Abu Bakar · 6 min read
Cardiology
Cardio-oncology is an emerging field that brings cardiologists and oncologists together to prevent and treat heart and vascular problems
Dr. Abu Bakar · 7 min read
Cardiology
Monoclonal antibodies that target the PCSK-9 protein are now part of routine discussions about managing high cholesterol (hyperlipidemia).
Dr. Abu Bakar · 8 min read
Cardiology
Once rare, infective endocarditis from injecting drugs is now a leading cause of heart valve surgery in many
Dr. Abu Bakar · 6 min read
Cardiology
For decades, low-density lipoprotein cholesterol (LDL-C) management has served as the bedrock of primary and secondary cardiovascular disease
Rayan Salih · 8 min read
Cardiology
Precision medicine is revolutionizing the field of cardiovascular medicine, and CYP2C19 genotyping has emerged as one of the
Dr. Abu Bakar · 9 min read
Cardiology
Nyra Medical has enrolled the first patient in the ENHANCE early feasibility study of its investigational CARLEN transcatheter
Dr. Abu Bakar · 9 min read
Cardiology
Aortic stenosis (AS) is a common heart valve problem in older adults, and clinicians often judge its severity by
Dr. Abu Bakar · 7 min read
Cardiology
Mayo Clinic Florida is the first center to use the Impella 5.
Dr. Abu Bakar · 7 min read
Cardiology
Vascular rings are rare birth defects of the aortic arch that form a loop around a baby’s windpipe
Dr. Abu Bakar · 9 min read
One story a day
One health journey each morning — no advice, no alarm, just company for the road.
